---
title: "G Sachs Raises CSPC PHARMA  TP to HKD12.56, Highlights mRNA Vaccines"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296588621.md"
description: "Goldman Sachs raised its target price for CSPC Pharma to HKD12.56 from HKD12.14, maintaining a Buy rating. The firm highlighted the company's mRNA vaccine platform as a key growth driver, noting that the therapeutic HPV mRNA vaccine has reached Phase II trials with encouraging data. While Q2 revenue surged 94% YoY due to licensing fees, core earnings remained flat. Goldman Sachs slightly increased earnings forecasts for 2026-2028."
datetime: "2026-08-21T08:31:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296588621.md)
  - [en](https://longbridge.com/en/news/296588621.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296588621.md)
generator: "portal-rs"
---

# G Sachs Raises CSPC PHARMA  TP to HKD12.56, Highlights mRNA Vaccines

G Sachs published a research report stating that driven by licensing fee income of about RMB5.7 billion, CSPC PHARMA (01093.HK) -0.330 (-3.466%) Short selling $93.64M; Ratio 15.408% 's 2Q revenue surged 94% YoY, while finished drug sales grew 16% YoY, accelerating from 6% growth in 1Q. Net profit jumped 389% YoY. Excluding the licensing fee income recognized in 2Q, core earnings were estimated to remain broadly flat YoY, as growth in R&D and administrative expenses continued to outpace product sales growth.

G Sachs said the development of the mRNA platform has become a key highlight. The group's therapeutic HPV mRNA vaccine has advanced to Phase II clinical trials, with encouraging early-stage data. The COVID mRNA vaccine project combined with PD-1 for solid tumors has also commenced. Management emphasized that identifying shared neoantigens through large oncology databases and AI antigen screening will enhance vaccine scalability and development efficiency. G Sachs raised its 2026-2028 earnings forecasts for CSPC PHARMA (01093.HK) -0.330 (-3.466%) Short selling $93.64M; Ratio 15.408% by 0.2% to 1.7%, lifted the TP from HKD12.14 to HKD12.56, and maintained the Buy rating.(gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-21 12:25.)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [CSPC wins China clinical trial approval for SYH2083 dry eye drops](https://longbridge.com/en/news/298295585.md)
- [CSPC PHARMA  Monkeypox mRNA Vaccine Approved for US Clinical Trials](https://longbridge.com/en/news/295420344.md)
- [CSPC says FDA clears US clinical trial for SYS 6037 mpox mRNA vaccine](https://longbridge.com/en/news/295395119.md)
- [CSPC Pharma wins China NMPA clearance to start Phase 1 trial of SYH2092 obesity drug](https://longbridge.com/en/news/297512143.md)
- [ME Therapeutics advances two CD19/CD22 in vivo CAR lead constructs in preclinical testing](https://longbridge.com/en/news/298324165.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**